Insitro

South San Francisco, CA, United States All United States companies → — Founded 2018

AI Research Lab Biotech / Drug Discovery

Oncology

Drug Discovery & Research Lab & Diagnostics

Series C

Website Claim this company

Products

Insitro

Drug Discovery & Research

Insitro combines automated cellular experiments with population-scale genetics to build Physical AI systems that reveal causal drivers of human disease and deliver targeted therapeutics.

See all 1 product →

About Insitro

Insitro is a biotechnology company that leverages machine learning (ML) and high-throughput biology to revolutionize drug discovery and development. The company aims to address the significant challenges in pharmaceutical R&D, such as low success rates and lengthy development timelines, by applying a data-driven approach. Insitro generates and integrates massive, high-quality, multi-modal datasets from automated cellular experiments and population-scale human genetics. This data fuels their proprietary AI platforms, including “Virtual Human™” and “TherML™”, to build predictive models of disease, identify causal biological drivers, prioritize therapeutic targets, and design novel drug candidates across various modalities like small molecules, oligonucleotides, and complex biologics.

For physicians, Insitro’s approach signifies a potential paradigm shift in how new medicines are brought to patients. By focusing on causal human biology and integrating diverse data types, Insitro seeks to develop therapeutics with a higher probability of success. Their work spans therapeutic areas such as metabolic diseases (including obesity and metabolic dysfunction-associated steatotic liver disease), neuroscience (including amyotrophic lateral sclerosis – ALS), and oncology. Through collaborations with major pharmaceutical companies like Bristol Myers Squibb and Eli Lilly, Insitro is advancing both internal and partnered programs, aiming to accelerate the delivery of transformative medicines to patients.

Focus Areas

metabolic disease neuroscience oncology drug discovery drug development machine learning AI high-throughput biology target identification small molecule discovery therapeutic design

Business Intelligence

Technology

Insitro's platform, called "Virtual Human™", is a genetically anchored, causal AI engine built on a large integrated multimodal corpus of human clinical and cellular data. It aims to reveal how disease begins, progresses, and can be resolved, identifying causal disease targets. They also have TherML™ (Therapeutic Machine Learning) platform, a modality-agnostic, AI-driven therapeutics design engine spanning small molecules, oligonucleotides, and complex biologics. The platform integrates automated laboratory generation of multimodal cellular data with human cohort and genetic data, applying machine learning and generative AI.

What Physicians Need to Know

Metabolic Disease

Insitro focuses on metabolic diseases, including obesity, brown adipose tissue biology, and metabolic dysfunction-associated steatotic liver disease (MASLD). They leverage AI and machine learning to identify genetic drivers and develop therapeutics for these conditions.

Neuroscience

In neuroscience, Insitro emphasizes amyotrophic lateral sclerosis (ALS) and related neurodegenerative biology, often through partnerships. Their platform identifies novel genetic modulators and targets for ALS, aiming for disease-modifying therapies.

Oncology

Oncology is part of Insitro's broader pipeline, utilizing their platform to discover and develop therapeutics.

Drug Discovery & Development

Insitro applies machine learning and large-scale human and cellular data to discover and develop therapeutics. They aim to accelerate target selection and the design of effective treatments, moving from stochastic screening to predictive, adaptive engineering.

Machine Learning & AI

Insitro is an AI therapeutics company built on causal biology. They integrate multimodal human cohort data, genetics, and high-content cellular data generated in automated laboratories, applying machine learning and generative AI to build phenotypic disease models, identify genetically supported targets, and guide chemistry and therapeutic design.

High-Throughput Biology

The company combines automated laboratory generation of multimodal cellular data with human cohort and genetic data to identify causal biology. They systematically construct large, well-labeled human cellular datasets in-house, designed explicitly for model learning.

Target Identification

Insitro's 'Virtual Human' platform, a genetically anchored causal AI engine, reveals how disease begins, progresses, and can be resolved, precisely identifying causal disease targets prior to candidate optimization.

Small Molecule Discovery & Therapeutic Design

Their TherMLu2122 platform is a modality-agnostic, AI-driven therapeutics design engine spanning small molecules, oligonucleotides, and complex biologics. It shifts drug discovery from stochastic screening to predictive, adaptive engineering.

Physician Tip

For physicians, Insitro's approach means a potential for more precisely targeted and effective therapies, developed faster and with a higher probability of success. Their focus on causal biology, driven by large-scale human and cellular data and advanced AI, aims to uncover the root causes of diseases rather than just treating symptoms. This could lead to novel treatments for complex conditions like MASLD, obesity, and ALS, where current options may be limited. The company's partnerships with major pharmaceutical companies like Eli Lilly and Bristol Myers Squibb also suggest a strong translational path for their discoveries into clinical development.

Insitro's platform integrates multimodal human cohort data, genetics, and high-content cellular data from automated laboratories. They apply machine learning and generative AI to build phenotypic disease models. Their technology stack includes Agentic Reasoning, Causality (statistical genetics, sequence foundation models), Representation (self-supervised learning, sparse autoencoders), Enhancement (imputation, generative modeling), and Data (image segmentation, active learning). They also have a ChemML platform for small molecule discovery and translational modeling.

At a glance

Founded 2018

HQ South San Francisco, CA, United States · United States

CEO Daphne Koller

Funding Series C

Products 1

Visit site

Products by Insitro

1 product in the directory

Insitro

Drug Discovery & Research

Insitro combines automated cellular experiments with population-scale genetics to build Physical AI systems that reveal causal drivers of human disease and deliver targeted therapeutics.

What the Web Says

Insitro is generally perceived as a pioneering company in the biotech and AI space, aiming to revolutionize drug discovery. Employee reviews highlight a strong scientific culture, brilliant colleagues, and a mission-driven environment, though some operational challenges typical of a rapidly growing startup are noted. Product-wise, the company is seen as innovative and potentially disruptive, though specific product reviews are less common given its B2B nature and early stage in drug development.

Overall: Positive

Strengths

Strong scientific culture and mission-driven environment
Brilliant, highly intelligent, and collaborative colleagues
Cutting-edge technology and innovative approach to drug discovery
Good compensation and benefits
Opportunity to work on impactful, challenging problems
Supportive leadership and focus on employee growth

Limitations

Rapid growth can lead to some organizational challenges and lack of clear processes
High expectations and demanding work environment
Potential for long hours, typical of a startup
Some reviews mention a lack of diversity in leadership
Communication can sometimes be a challenge across rapidly expanding teams
Specific product outcomes are long-term, so immediate impact can be hard to see

Based on reviews from: Glassdoor, Reddit, Healthcare IT News (general industry sentiment), Company website/press releases (for mission/vision)

Last updated: 2026-08-31

Videos

News, demos, and interviews about Insitro.

Loading videos...

Videos load interactively. If none appear, search YouTube for Insitro →

View all on YouTube

Press & Coverage

insitro Press Releases

insitro Presents New Data Demonstrating Its AI-Discovered MASH Candidate Shows Anti-Fibrotic Signal Beyond Liver-Fat Reduction at the American Diabetes Association 86th Scientific Sessions

Insitro presented new data at the American Diabetes Association 86th Scientific Sessions, showcasing its AI-discovered MASH candidate's anti-fibrotic signal, which extends beyond liver-fat reduction. The company is continuing IND-enabling studies for CTRO-1013 and anticipates it will enter first-in-human clinical trials this year.

2026-06

insitro Press Releases

insitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets

Insitro announced the expansion of its collaboration with Bristol Myers Squibb, with BMS nominating two additional therapeutic targets (ALS-2 and ALS-3) for Amyotrophic Lateral Sclerosis (ALS) discovered through insitro's AI-driven Virtual Humanu2122 platform. This expansion triggered a $10 million milestone payment to insitro.

2026-03

insitro Press Releases

insitro Appoints Joe Hand as Chief People Officer to Advance Talent Strategy for Next Stage of Development

Insitro appointed Joe Hand as Chief People Officer to further its talent strategy as the company enters its next phase of development. This appointment aims to strengthen the company's focus on its workforce.

2026-02

insitro Press Releases

insitro Completes First AI-Enabled Human Genetics Study of Brown Adipose Tissue, Shares Differentiated Targets with Anti-Obesity Effects

Insitro reported the completion of its first AI-enabled human genetics study of brown adipose tissue (BAT), identifying genetic loci associated with BAT biology. The study also revealed a prioritized target, BAT-01, which showed significant weight loss in preclinical models.

2026-02

insitro Press Releases

insitro to Acquire CombinAbleAI to Complete its Full Stack, Modality-Agnostic AI Platform for Drug Discovery and Design

Insitro announced its acquisition of CombinAbleAI and the launch of its TherMLu2122 (Therapeutic Machine Learning) platform, aiming to create a full-stack, modality-agnostic AI platform for drug discovery and design. This acquisition is expected to close in late January 2026.

2026-01

insitro Press Releases

insitro Validates AI-Enabled POSH Platform in Nature Communications, Bridging Critical Gap in Drug Discovery

Insitro validated its AI-enabled POSH platform in a publication in Nature Communications, highlighting its role in bridging a critical gap in drug discovery. The platform aims to accelerate the discovery of new medicines.

2025-12

insitro Press Releases

insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro's ChemML Discovery Platform

Insitro and Bristol Myers Squibb announced the extension of their collaboration to discover new molecules for ALS, leveraging insitro's AI-enabled ChemMLu2122 platform. This extension could provide up to $20 million in new funding and potential milestone payments exceeding $2 billion.

2025-10

SalesTools AI

Insitro Raises $400M Series C

Insitro successfully closed a $400 million Series C funding round, bringing its total raised capital to approximately $800 million. This funding will be used to accelerate product development, expand market reach, and strengthen its position in the biotech sector.

2025-10

Frequently Asked Questions

How does Insitro's application of machine learning and high-throughput biology specifically accelerate drug discovery and development for metabolic diseases, neuroscience, and oncology?

Insitro leverages machine learning and high-throughput biology to create predictive models of disease, enabling the identification of novel drug targets and the design of more effective therapeutics. This approach allows for a more efficient screening of potential drug candidates and a deeper understanding of disease mechanisms across metabolic, neurological, and oncological indications.

What are Insitro's current therapeutic pipelines or products in metabolic disease, neuroscience, and oncology, and what stage of development are they in?

Insitro is actively engaged in developing therapeutics across metabolic diseases, neuroscience, and oncology. While specific product details and their development stages are often subject to partnership agreements and ongoing research, their focus is on advancing programs from target identification through to preclinical and early clinical development.

How does Insitro ensure the compliance and regulatory adherence of its AI-driven drug discovery processes and the resulting therapeutic candidates?

Insitro integrates regulatory considerations throughout its drug discovery and development processes, ensuring that its AI-driven approaches and therapeutic candidates meet industry standards and regulatory requirements. This includes rigorous data governance, validation of computational models, and adherence to ethical guidelines for AI in healthcare.

What kind of support and partnership models does Insitro offer to healthcare organizations or academic institutions interested in collaborating on drug discovery efforts?

Insitro actively seeks partnerships with healthcare organizations and academic institutions, offering collaborative models that can range from joint research initiatives to licensing agreements. They provide scientific and technical support, leveraging their AI and high-throughput biology platforms to accelerate partners' drug discovery programs.

What is Insitro's long-term vision for addressing unmet medical needs in metabolic disease, neuroscience, and oncology, and what is the company's stability and funding outlook?

Insitro's long-term vision is to transform drug discovery by industrializing the process of therapeutic development, ultimately delivering more effective medicines to patients with metabolic diseases, neurological disorders, and cancer. The company has secured significant funding rounds and established key partnerships, indicating strong financial stability and a positive outlook for continued growth and innovation.

How does Insitro's approach to target identification and small molecule discovery differ from traditional methods, and what advantages does it offer in terms of therapeutic design?

Insitro's approach to target identification and small molecule discovery utilizes machine learning to analyze vast biological datasets, identifying novel targets and predicting optimal small molecule structures with greater precision and speed than traditional methods. This allows for the design of therapeutics with improved efficacy and reduced off-target effects.